Study guide

17.2 Genitourinary Emergencies: UTI & Pyelonephritis, Renal Colic, Urinary Retention, Priapism & Scrotal Infections

BCEMP Board Certified Emergency Medicine Pharmacist Exam

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Introduction, Triage, and Resuscitation Fundamentals

1.1 BCEMP Exam Logistics, Content Outlines & Scoring 1.2 Emergency Triage Systems (ESI) & Pre-Hospital Care Coordination 1.3 Resuscitation Pharmacology, Pharmacokinetics & Vascular Access

2 Chapter 2: Cardiac Arrest and Dysrhythmias

2.1 Adult Cardiac Arrest & ACLS Pharmacotherapy Protocols 2.2 Acute Tachyarrhythmias: Narrow- and Wide-Complex Management 2.3 Symptomatic Bradycardia & Vasoactive Chronotropic Support 2.4 Post-Cardiac Arrest Care & Targeted Temperature Management (TTM)

3 Chapter 3: Shock and Hemodynamic Resuscitation

3.1 Sepsis & Septic Shock: Surviving Sepsis Campaign 2026 Resuscitation 3.2 Cardiogenic & Obstructive Shock, Mechanical Circulatory Support & LVADs 3.3 Hypovolemic & Hemorrhagic Shock Fluid Protocols

4 Chapter 4: Airway Management and Rapid Sequence Intubation (RSI)

4.1 Rapid Sequence Intubation (RSI) Process & Pretreatment Agents 4.2 RSI Induction Agents: Pharmacology, Selection & Dosing 4.3 Neuromuscular Blocking Agents & Post-Intubation Analgosedation

5 Chapter 5: Neurocritical Care and Neurologic Emergencies

5.1 Acute Ischemic Stroke: Thrombolysis & Blood Pressure Control 5.2 Intracranial Hemorrhage & Elevated ICP Pharmacotherapy 5.3 Status Epilepticus: Tiered Emergent Anticonvulsant Therapy 5.4 Traumatic Brain Injury & Spinal Cord Emergencies

6 Chapter 6: Acute Coronary Syndromes and Acute Heart Failure

6.1 Acute Coronary Syndromes: STEMI & NSTE-ACS Pharmacotherapy 6.2 Acute Decompensated Heart Failure & Cardiogenic Pulmonary Edema 6.3 Hypertensive Crises: Emergencies, Urgencies & Target Blood Pressure

7 Chapter 7: Pulmonary and Allergic Emergencies

7.1 Acute Pulmonary Embolism: Risk Stratification & Thrombolytic Therapy 7.2 Severe Asthma Exacerbation & COPD Acute Management 7.3 Anaphylaxis & Severe Allergic Reactions: Acute Epinephrine Protocols

8 Chapter 8: Clinical Toxicology: Approach to Poisoning and Common Overdoses

8.1 Approach to the Poisoned Patient: Poison Centers, Toxidromes, Decontamination & Enhanced Elimination 8.2 Acetaminophen Overdose & N-Acetylcysteine Dosing Strategies 8.3 Salicylate Toxicity & Toxic Alcohol Management (Fomepizole) 8.4 Opioid Toxicity & Sedative-Hypnotic/Alcohol Withdrawal Syndromes 8.5 Beta-Blocker & Calcium Channel Blocker Toxicity (HIET, Calcium, Glucagon)

9 Chapter 9: Toxicology: Specialized Poisonings and Antidotes

9.1 Digoxin, Tricyclic Antidepressants & Anticholinergic Toxicity 9.2 Cyanide, Carbon Monoxide & Organophosphate/Cholinergic Toxins 9.3 Snake and Spider Envenomations & Heavy Metal Chelation 9.4 Additional Antidotes: Methemoglobinemia, Isoniazid, Sulfonylureas, Valproate, Sympathomimetics & LAST

10 Chapter 10: Hemostasis, Anticoagulant Reversal, and Hematology

10.1 DOAC & Warfarin Reversal: Specific Reversal Agents & 4F-PCC 10.2 Heparin-Induced Thrombocytopenia (HIT) & Direct Thrombin Inhibitors 10.3 Sickle Cell Vaso-Occlusive Crises & Acute Chest Syndrome

11 Chapter 11: Endocrine, Electrolyte, and Metabolic Emergencies

11.1 Diabetic Ketoacidosis (DKA) & Hyperosmolar Hyperglycemic State (HHS) 11.2 Severe Electrolyte Emergencies: Hyperkalemia & Hyponatremia 11.3 Endocrine Crises: Thyroid Storm, Myxedema Coma & Acute Adrenal Crisis 11.4 Acute Kidney Injury, Dialyzability & Drug Dosing during RRT

12 Chapter 12: Infectious Diseases and Antimicrobial Stewardship

12.1 Severe Community & Hospital-Acquired Infections in the ED 12.2 Skin & Soft Tissue, STI, and Vector-Borne Emergencies 12.3 ED Antimicrobial Stewardship & Rapid Microbiologic Diagnostics

13 Chapter 13: Special Populations: Pediatrics, Trauma, and Obstetrics

13.1 Pediatric Resuscitation, Status Epilepticus & PALS Pharmacotherapy 13.2 Trauma Pharmacotherapy: Massive Transfusion, TXA, Open Fractures, Tetanus & Burns 13.3 Obstetric & Gynecologic Emergencies: Preeclampsia, Eclampsia & PPH

14 Chapter 14: Medication Safety, ED Operations, and Disaster Preparedness

14.1 ED High-Alert Medications, Error Reporting & Technology Safeguards 14.2 ED Workflow, Transitions of Care & Boarding Patient Management 14.3 Mass Casualty Incidents, CBRNE Countermeasures & Strategic Stockpiles

15 Chapter 15: Biostatistics, Study Design, and Literature Evaluation

15.1 Biostatistics & Hypothesis Testing: Power, Errors & Interpretations 15.2 Clinical Study Designs & Measures of Effect 15.3 Literature Evaluation, Clinical Guidelines & Research Conduct in the ED

16 Chapter 16: Medical Devices, Ventilation, and Medication Delivery

16.1 Mechanical Ventilation, Noninvasive Ventilation & High-Flow Oxygen: What the Pharmacist Must Know 16.2 Vascular Access, Enteral Tubes, Drains & Extravasation Management 16.3 Infusion Pumps, Patient-Owned Devices & Medication Delivery Device Counseling

17 Chapter 17: Organ-System Emergencies: GI, GU, Oncology, Neurology, ENT, Pain, and Psychiatry

17.1 Gastrointestinal & Hepatic Emergencies: GI Bleeding, Cirrhosis Complications, Pancreatitis & Vomiting 17.2 Genitourinary Emergencies: UTI & Pyelonephritis, Renal Colic, Urinary Retention, Priapism & Scrotal Infections 17.3 Oncologic, Immunotherapy & Hematologic Emergencies: Febrile Neutropenia, TLS, Hypercalcemia, irAEs, CAR-T, Hemophilia & TTP 17.4 Headache & Neuromuscular Emergencies: Migraine, Cluster, Myasthenic Crisis, Guillain-Barré & Bell's Palsy 17.5 Ophthalmologic, ENT & Dental Emergencies: Eye Injuries, Angle Closure, Angioedema, Epistaxis, Ear & Throat Infections and Dental Pain 17.6 Acute Pain Management & Procedural Sedation and Analgesia in the ED 17.7 Psychiatric Emergencies: Severe Agitation, Serotonin Syndrome, NMS, Lithium Toxicity & Psychotropic Overdose

18 Chapter 18: Special Populations, Medication Access, and Professional Practice

18.1 Pharmacogenomics, Adverse Drug Events & High-Risk Drug Interactions in Emergency Care 18.2 Special Populations: Older Adults, Extremes of Weight, Pregnancy & Lactation, and Immunocompromised Patients 18.3 Social Determinants of Health, Health Literacy & Medication Access at ED Discharge 18.4 Healthcare Regulations & Standards: FDA, REMS, Bar Coding, DEA, CMS, EMTALA, The Joint Commission, NIOSH & USP 18.5 Formulary & Inventory Management, Drug Shortages, Antidote Stocking & Clinical Decision Support 18.6 Quality Improvement, Practice Standards & Interprofessional Collaboration (Protocols, Teamwork & Debriefing)

17.2 Genitourinary Emergencies: UTI & Pyelonephritis, Renal Colic, Urinary Retention, Priapism & Scrotal Infections

Key Takeaways Explain This Topic AI

The 2025 IDSA guideline defines uncomplicated UTI as bladder-limited infection in women or men, and complicated UTI as infection with fever, systemic signs, flank pain or costovertebral angle tenderness.

For complicated UTI, including pyelonephritis and Gram-negative bacteremia, IDSA 2025 suggests 5 to 7 days of a fluoroquinolone or 7 days of another effective agent once the patient is improving.

Asymptomatic bacteriuria is treated only in pregnancy and before urologic procedures that breach the mucosa, not in older adults with nonspecific confusion or in catheterized patients.

NSAIDs are first-line for renal colic, and an alpha-blocker such as tamsulosin can be offered for distal ureteral stones of 10 mm or less.

Ischemic priapism is treated with aspiration and intracavernosal phenylephrine 100 to 500 mcg/mL in 1 mL doses at least 5 minutes apart for up to 1 hour (AUA/SMSNA 2022).

Last updated: October 2026

17.2 Genitourinary Emergencies: UTI & Pyelonephritis, Renal Colic, Urinary Retention, Priapism & Scrotal Infections

Note

Exam scope: the genitourinary part of 2025 outline subtopic 2B3. Obstetric emergencies are covered in Section 13.3, sexually transmitted infections in Section 12.2, and ED culture callbacks in Section 12.3.

Classifying Urinary Tract Infection (IDSA 2025)

The 2025 IDSA guideline on complicated UTI replaced older definitions that labeled every UTI in a man, or in a patient with a urologic abnormality, as "complicated":

Category Definition Examples

Uncomplicated UTI Infection confined to the bladder in women or men : dysuria, urgency, frequency, suprapubic pain, with no fever or systemic signs Acute cystitis

Complicated UTI Infection beyond the bladder: fever, chills or rigors, hemodynamic instability, flank pain or costovertebral angle tenderness Pyelonephritis, febrile catheter-associated UTI, urosepsis, many prostatic infections

Asymptomatic Bacteriuria (IDSA 2019)

Bacteria in the urine without urinary symptoms is common, especially in older adults and catheterized patients. Screen and treat only:

  • In pregnancy
  • Before urologic procedures that breach the mucosa

Do not treat asymptomatic bacteriuria in older adults with falls or delirium but no fever or systemic signs, in people with diabetes, or in patients with long-term catheters. Pyuria alone is not a reason to treat. Unnecessary antibiotics cause C. difficile infection, resistance and adverse effects. Look for other causes of the confusion.

Acute Uncomplicated Cystitis

Agent Regimen Notes

Nitrofurantoin monohydrate/macrocrystals 100 mg twice daily for 5 days Bladder levels only, so not for pyelonephritis; avoid when CrCl is below 30 mL/min (2023 AGS Beers Criteria)

Trimethoprim-sulfamethoxazole 160/800 mg twice daily for 3 days Use only if local resistance is below about 20% and the patient has not used it in the past 3 months; watch potassium and warfarin interactions

  • Fosfomycin 3 g single dose Convenient, but slightly less effective
  • Pivmecillinam (FDA-approved 2024) 185 mg three times daily for 3 to 7 days Penicillin-class agent for women

Gepotidacin (FDA-approved 2025) 1,500 mg twice daily for 5 days First-in-class triazaacenaphthylene for women and girls 12 years and older weighing at least 40 kg; review interactions and QT risk

Oral beta-lactams Amoxicillin-clavulanate, cefpodoxime, cephalexin Less effective than first-line agents

Fluoroquinolones Ciprofloxacin, levofloxacin Reserved for patients with no alternatives because of boxed warnings for tendon, nerve and CNS harm (Section 12.3)

Sulopenem etzadroxil with probenecid (2024) is another oral option for women with limited alternatives.

  • Complicated UTI and Pyelonephritis (IDSA 2025)
  • Empiric Therapy

IDSA recommends a four-step approach:

Assess severity : sepsis or septic shock calls for broader initial coverage.

Review prior urine cultures from the past 3 to 6 months, and avoid drugs to which an earlier isolate was resistant.

Consider patient risks , such as recent antibiotics, healthcare exposure, allergies and kidney function.

Use the local antibiogram .

A patient in septic shock who has a history of an ESBL-producing organism should start a carbapenem. A stable patient without resistance risks can receive ceftriaxone, or a fluoroquinolone if local resistance allows.

IV-to-Oral Switch and Duration

Switch to a well-absorbed oral agent active against the isolate once the patient is improving and can take oral medication.

Duration for patients improving on effective therapy:

  • 5 to 7 days of a fluoroquinolone , or
  • 7 days of a non-fluoroquinolone agent ,

rather than 10 to 14 days, including patients with Gram-negative bacteremia from a urinary source.

Days are counted from the first day of effective therapy.

Longer courses still make sense for slow responders, undrained abscesses, ongoing obstruction or suspected bacterial prostatitis.

Special Situations

Pregnancy: cystitis and asymptomatic bacteriuria are treated. Pyelonephritis usually means admission for IV ceftriaxone. Avoid fluoroquinolones. ACOG advises using nitrofurantoin and sulfonamides in the first trimester only when no suitable alternative exists, and avoiding sulfonamides near term.

Infected obstructing stone: this is a urologic emergency that needs urgent decompression (stent or nephrostomy) as well as antibiotics.

Catheter-associated UTI: replace a catheter that has been in place more than 2 weeks before collecting the culture and starting therapy.

Renal Colic

NSAIDs are first-line. For ketorolac, 10 mg IV gives about the same pain relief as 15 or 30 mg. Avoid NSAIDs in AKI, advanced CKD, a solitary kidney or active bleeding.

Opioids are add-on therapy for pain that persists. IV acetaminophen and IV lidocaine have been studied, with mixed results for lidocaine.

Medical expulsive therapy: the AUA suggests offering an alpha-blocker, such as tamsulosin 0.4 mg daily for up to about 4 weeks, for distal ureteral stones of 10 mm or less . Benefit is greatest for stones of 5 to 10 mm; the STONE trial (2018) showed no overall benefit for stones under 9 mm.

Urgent urology referral: fever with obstruction, AKI, a solitary kidney, or pain or vomiting that cannot be controlled.

Acute Urinary Retention

Medications are a common cause or contributor:

  • Anticholinergics: diphenhydramine, hydroxyzine, tricyclic antidepressants, oxybutynin, scopolamine
  • Opioids , especially intrathecal or high-dose
  • Sympathomimetics: pseudoephedrine, phenylephrine, amphetamines
  • Antipsychotics and some muscle relaxants

Decompress the bladder with a catheter. In men with benign prostatic hyperplasia, starting an alpha-blocker (tamsulosin 0.4 mg daily) at least 2 to 3 days before a trial without the catheter improves the chance of voiding. Stop or replace the causative drugs.

Ischemic Priapism

Ischemic (low-flow) priapism is a painful, rigid erection lasting more than 4 hours . It is a compartment syndrome of the penis, and the risk of permanent erectile dysfunction rises with time.

Drug causes:

Intracavernosal injection therapy (alprostadil, papaverine, phentolamine mixtures)

Trazodone and antipsychotics with alpha-1 blocking activity (for example chlorpromazine, risperidone, quetiapine)

Cocaine and other illicit drugs, and PDE5 inhibitors (less commonly)

Sickle cell disease is the most common cause in children.

Treatment (AUA/SMSNA 2022)

First-line treatment is corporal aspiration, with or without irrigation, plus intracavernosal phenylephrine .

Phenylephrine: 100 to 500 mcg/mL, given as 1 mL injections at least 5 minutes apart, for up to about 1 hour. Pharmacy should prepare it in advance to avoid calculation errors.

Monitor blood pressure and heart rate; watch for hypertension and reflex bradycardia, especially in patients with cardiovascular disease.

In sickle cell disease, give the same urologic first-line treatment; do not delay it while giving hydration, oxygen or exchange transfusion.

Preparation example: phenylephrine 10 mg/mL. For 500 mcg/mL , add 1 mL (10 mg) to 19 mL of normal saline for a 20 mL total. For 100 mcg/mL , add 1 mL to 99 mL of normal saline. Draw doses into labeled 1 mL syringes.

Scrotal Emergencies

Testicular torsion is a surgical emergency; give analgesia, but do not delay urology.

Acute epididymitis (CDC 2021 STI Treatment Guidelines):

Likely cause Regimen

Chlamydia or gonorrhea (sexually active, typically younger) Ceftriaxone 500 mg IM once (1 g if 150 kg or more) plus doxycycline 100 mg twice daily for 10 days

Sexually transmitted organisms and enteric organisms (insertive anal intercourse) Ceftriaxone 500 mg IM once plus levofloxacin 500 mg daily for 10 days

Enteric organisms only (no STI risk, often after instrumentation or with BPH) Levofloxacin 500 mg daily for 10 days

Fournier gangrene is a necrotizing soft tissue infection that needs emergency surgery and broad antibiotics (Section 12.1).